A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

  • STATUS
    Not Recruiting
  • End date
    Feb 2, 2029
  • participants needed
    164
  • sponsor
    AbbVie
Updated on 1 September 2021
Investigator
AbbVie_Call Center
Primary Contact
McGill University Health Center Research Institute /ID# 223976 (6.0 mi away) Contact
+134 other location

Summary

www.MyelofibrosisResearch.com

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Description


Details
Condition Myelofibrosis
Treatment Ruxolitinib, Navitoclax
Clinical Study IdentifierNCT03222609
SponsorAbbVie
Last Modified on1 September 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note